The FDA has approved dupilumab as the first targeted treatment for adults with bullous pemphigoid, showing improved remission rates and reduced corticosteroid use.
A controversial HHS document supporting RFK Jr.'s rollback of COVID vaccine guidance relies on disputed or misrepresented science, prompting outrage from health experts who call it “willful medical disinformation.”
Examine the FDA's stringent sunscreen regulations and the impact on the availability of advanced sunscreen ingredients in the U.S., as well as bipartisan legislative efforts to modernize these standards.
2023 brought record-breaking heat waves in the United States, significantly impacting vulnerable groups. Analysis by the CDC revealed a substantial number of heat-related illness (HRI) emergency department visits, resulting in multiple public health alerts.
Conexiant
Daily News
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
Thank you for signing up for the Daily News alerts. You will begin receiving them shortly.
The World Bank's Pandemic Fund secures substantial contributions from the U.S. and Germany, aiming to prevent a recurrence of a crisis similar to COVID-19.
NIH director, Dr. Monica M. Bertagnolli, is stepping down after launching major initiatives in women's health and long COVID research, indicating optimism for their continuation under new leadership.
The FDA approved dupilumab as the first targeted therapy for chronic spontaneous urticaria in patients aged 12 years and older uncontrolled on antihistamines.